CCC
RMD icon

Crescent Capital Consulting’s ResMed RMD Stock Holding History

Crescent Capital Consulting’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$2K Hold
7
– – ﹤0.01% 479
2021
Q3 		$2K Hold
7
– – ﹤0.01% 517
2021
Q2 		$2K Hold
7
– – ﹤0.01% 460
2021
Q1 		$1K Hold
7
– – ﹤0.01% 480
2020
Q4 		$1K Buy
+7
New +$1.4K ﹤0.01% 451

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Crescent Capital Consulting's RMD Position: Q4 2021 in Review

Crescent Capital Consulting held its ResMed (RMD) position steady in Q4 2021 at 7 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #479.

Crescent Capital Consulting first reported a position in RMD in Q4 2020 and has held it in 5 quarters since. 723 funds tracked by Wall St. Rank hold RMD as of Q4 2021.

  • Crescent Capital Consulting held 7 shares of ResMed worth $2K as of Q4 2021.
  • Crescent Capital Consulting left its ResMed share count unchanged in Q4 2021.
  • ResMed made up ﹤0.01% of Crescent Capital Consulting's portfolio in Q4 2021, its #479 holding.
  • Crescent Capital Consulting first reported a position in ResMed in Q4 2020 and has held it in 5 quarters since.
  • 723 funds tracked by Wall St. Rank held ResMed as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.